News and Announcements
Prescient Fully Underwritten Up To Target Amount of $1.03 million
- Published October 30, 2015 12:00PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th October 215, ASX Announcement
- Funds to drive next stage development of promising lead drug asset PTX-200
- SPP fully underwritten by Patersons Securities up to the target amount of $1.03 million and anticipated to fund key activities and milestones to Q3 2016
- Multiple value creation points in next 12 months from PTX-200 trials in breast, ovarian cancers and Acute Myeloid Leukemia
Cancer drug development company Prescient Therapeutics Limited (ASX:PTX) (Company) is pleased to announce a Share Purchase Plan (SPP) fully underwritten up to the target amount of $1.03 million to underpin next stage development of its lead oncology assets.
The SPP provides the opportunity for existing shareholders to subscribe for up to $15,000 in new fully paid ordinary share (New Shares) without inuring brokerage or other transaction costs.
To read the full announcement, please click here.
To read the Share Purchase Plan, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
